Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 4Phase NA 3Phase 1/2 2Phase 4 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 276Pain, Postoperative 14Neoplasm Metastasis 12Neoplasms 9Prostatic Neoplasms 8Ovarian Neoplasms 7Triple Negative Breast Neoplasms 6Pain 6Osteoporosis 6Seroma 5Colorectal Neoplasms 5Cardiotoxicity 5Breast Diseases 4Breast Cancer Female 4Neutropenia 3Melanoma 3Mastodynia 3Lymphedema 3Lung Neoplasms 3Head and Neck Neoplasms 3Brain Neoplasms 3Bone Diseases, Metabolic 3Vomiting 2Uterine Cervical Neoplasms 2Stomach Neoplasms 2Sleep Initiation and Maintenance Disorders 2Skin Diseases 2Obesity 2Neurotoxicity Syndromes 2Multiple Myeloma 2

Interventions

eribulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Drug-Related Side Effects and Adverse Reactions × Breast × Clear all
NCT02864030 2021-03-04

PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment

Oncologia Medica dell'Ospedale Fatebenefratelli

Phase 4 Completed
200 enrolled
Breast

Breast Neoplasms, Neurotoxicity Syndromes, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡